Editas Medicine, Inc. Share Price

Equities

EDIT

US28106W1036

Biotechnology & Medical Research

Market Closed - Nasdaq 21:00:00 12/04/2024 BST 5-day change 1st Jan Change
6.21 USD -5.62% Intraday chart for Editas Medicine, Inc. -7.59% -38.70%
Sales 2024 * 34.3M 2.75B Sales 2025 * 24.82M 1.99B Capitalization 508M 40.81B
Net income 2024 * -206M -16.55B Net income 2025 * -242M -19.44B EV / Sales 2024 * 7.45 x
Net cash position 2024 * 252M 20.28B Net cash position 2025 * 95M 7.63B EV / Sales 2025 * 16.6 x
P/E ratio 2024 *
-2.53 x
P/E ratio 2025 *
-2.43 x
Employees 265
Yield 2024 *
-
Yield 2025 *
-
Free-Float 99.09%
More Fundamentals * Assessed data
Dynamic Chart
1 day-5.62%
1 week-7.59%
Current month-16.31%
1 month-27.87%
3 months-31.53%
6 months-9.21%
Current year-38.70%
More quotes
1 week
6.13
Extreme 6.13
7.03
1 month
6.13
Extreme 6.13
8.59
Current year
6.13
Extreme 6.13
11.58
1 year
6.08
Extreme 6.0799
11.91
3 years
6.08
Extreme 6.0799
73.03
5 years
6.08
Extreme 6.0799
99.95
10 years
6.08
Extreme 6.0799
99.95
More quotes
Managers TitleAgeSince
Chief Executive Officer 59 31/05/22
Director of Finance/CFO 57 16/05/23
Chief Tech/Sci/R&D Officer - 23/07/23
Members of the board TitleAgeSince
Chairman 63 02/09/21
Director/Board Member 71 05/02/19
Director/Board Member 61 27/07/16
More insiders
Date Price Change Volume
12/04/24 6.21 -5.62% 2,024,621
11/04/24 6.58 -0.75% 1,476,420
10/04/24 6.63 -5.42% 2,134,892
09/04/24 7.01 +4.32% 1,568,958
08/04/24 6.72 0.00% 1,040,296

Delayed Quote Nasdaq, April 12, 2024 at 09:00 pm

More quotes
Editas Medicine, Inc. is a clinical-stage genome editing company. The Company is focused on developing potentially transformative genomic medicines to treat a broad range of serious diseases. It has developed a proprietary gene editing platform based on CRISPR technology. CRISPR uses a protein- ribonucleic acid (RNA) complex composed of an enzyme, including either CRISPR associated protein 9 (Cas9) or Cas12a (CRISPR from Prevotella and Francisella 1, also known as Cpf1), bound to a guide ribonucleic acid (RNA) molecule designed to recognize a particular deoxyribonucleic acid (DNA) sequence. It is engaged in the development of vivo administered gene editing medicines, in which the medicine is injected or infused into the patient to edit the cells inside their body. Its lead program, reni-cel, is an experimental ex vivo gene-edited medicine to treat sickle cell disease (SCD), a severe inherited blood disease that causes premature death, and transfusion-dependent beta thalassemia (TDT).
Related indices
More about the company
Trading Rating
Investor Rating
ESG Refinitiv
C+
More Ratings
Sell
Consensus
Buy
Mean consensus
OUTPERFORM
Number of Analysts
18
Last Close Price
6.21 USD
Average target price
15.4 USD
Spread / Average Target
+147.99%
Consensus